Transparency Market Research Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample Published Date: March 2014 Multi User License: US $ 7595 Corporate User License: US $ 10595 159 Pages Report REPORT DESCRIPTION Pharmacovigilance Market Expected to Reach USD 5.0 Billion Globally in 2019: Transparency Market Research According to a new market report published by Transparency Market Research "Pharmacovigilance Market [Clinical Trial Phases (Pre-Clinical Studies, Phase I, Phase II, Phase III, Phase IV or Post-Marketing Surveillance) and Service Providers (In-House and Contract Outsourcing] - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019," the global pharmacovigilance market was valued at USD 2,147.3 million in 2012 and is estimated to reach a market worth USD 5,008.2 million in 2019 at a CAGR of 12.9% from 2013 to 2019. Browse TOC of Pharmacovigilance Market Report: http://www.transparencymarketresearch.com/pharmacovigilance-market.html Rising regulatory concerns, public safety issues, tough inspection regime coupled with instant need of patient reporting has provided the much needed impetus for the pharmacovigilance market. According to World Health Organization (WHO) the pharmacovigilance is defined as the science and activities involved in the detection, assessment, monitoring and evaluation of adverse events or any drug related problems of the medicinal products. The main objective of pharmacovigilance is the safer administration of medicinal products, which is attained through awareness of precise, timely and relevant clinical safety information of medical products.
The rapid growth of global pharmaceutical industry has resulted in the innovation in the number of medicinal products that can treat, cure and prevent various disorders. Although, the newly developed products have various benefits, these are allied with number of adverse drug events that can range from mild to severe side effects often resulting in disabilities, illness and death. In order to evade this, early detection of the adverse drug reactions in clinical trials and active clinical phase IV or post-marketing surveillance is imperative to identify these adverse events associate with the products. Nowadays, all the pharmaceutical companies are actively involved in the safety assessment and monitoring of medicinal products which are under clinical trials and also for marketed products. Until recently, the scope of the drug safety reporting was restricted to assessment and monitoring of very small number of medicinal products but now it has been extended to various products such as medical devices, traditional medicines, blood products, vaccines, etc. The guidelines for the appropriate implementation of drug safety reporting services has been formulated by various national and international regulatory authorities such as the World Health Organization (WHO) and United States Food and Drug Administration (USFDA) are aiding in enhancement of the overall PV activities being conducted by the pharmaceutical companies The global market for pharmacovigilance services is segmented based on type of clinical trial phases, service providers and methods used in drug safety reporting. Based on type of clinical trial phases, the market is categorized in to preclinical studies, phase I, II, III, IV or post-marketing surveillance services market. Among these, the market for clinical trial phase IV drug safety reporting services market accounts for the largest market share of 74.7% in 2012 and was valued to USD 1,604.8 million in the same year. This market is expected to lead the pharmacovigilance market till 2019 owing to rise in public safety issues coupled with growing regulatory concerns regarding safety of the marketed products. In addition, the market is segmented based on type of service providers by in-house and contract outsourcing services market. Among these, contract outsourcing pharmacovigilance services market accounts for the largest market share of 50.8% in 2012 and is forecast to grow at a healthy growth rate of 15.5% during the forecast period of 2013 to 2019. The contributing factors behind such an assessment include its high cost involvement, quality concerns, requirement of highly qualified professionals and growing regulatory concerns. Geographically, the North American region constituted the largest market for global pharmacovigilance market in 2012; however, Asia-Pacific is predicted to foresee the highest growth rate of 15.2% from 2013 to 2019. This growth has been attributed to large population base, low healthcare cost and high enrolment rate of patients. In addition, favorable government support, growing pharmaceutical industry would trigger the growth of this market in Asian-Pacific region.
The leading market players include Accenture, Plc, Bristol-Myers Squibb, Covance, Inc., Cognizant Technology Solutions, Icon, Plc.,iGATE Corporation, Novartis International AG, Parexel International Corporation, PRA International, Inc., Pharmaceutical Product Development, Inc. (PPD), Pfizer, Inc., Quintiles Transnational Corporation and Wipro Limited. The global pharmacovigilance market is segmented as follows: Global Pharmacovigilance Market, by Segments Pharmacovigilance Market Type of clinical trial phases Pre-Clinical Studies Phase I Phase II Phase III Phase IV or Post-marketing Surveillance Type of service providers In-House Contract Outsourcing Type of methods used in drug safety reporting Spontaneous reporting Intensified ADR reporting Targeted reporting Cohort event monitoring EHR monitoring Global Life Sciences BPO Market, by Geography North America Europe Asia-Pacific Rest of the World (ROW) TABLE OF CONTENTS Chapter 1 Introduction 1.1 Report Description 1.2 Research Methodology 1.3 Market Segmentation Chapter 2 Executive Summary
Chapter 3 Global Pharmacovigilance Market Dynamics 3.1 Introduction 3.1.1 Drivers 3.1.1.1 Rise in number of drug consumption 3.1.1.2 Rise in drug toxicity cases producing significant morbidity and mortality 3.1.1.3 Embracing new technologies to mitigate risk 3.1.1.4 Rise in adoption of pharmacovigilance outsourcing services 3.1.1.5 Globalization of drug development with shift from manufacturing activities from high cost to low cost regions 3.1.2 Restraints 3.1.2.1 Stringent and varied regulatory approval processes 3.1.3 Challenges 3.1.3.1 Lack of availability of skilled labor 3.2 Porter s Five Force Analysis: Global Pharmacovigilance Market 3.2.1 Bargaining Power of Suppliers 3.2.2 Bargaining Power of Buyers 3.2.3 Threat of New Entrants 3.2.4 Threat of Substitutes 3.2.5 Competitive Rivalry 3.3 Market Attractiveness Analysis of the Global Pharmacovigilance Market, by Geography 3.3.1 Market Attractiveness Analysis: Global Pharmacovigilance Market, 2012, by Geography Chapter 4 Global Pharmacovigilance Market, by Clinical Trial Phases 4.1 Overview 4.1.1 Preclinical Studies
Related & Recently Published Reports by Transparency Market Research Polypropylene Market: http://www.transparencymarketresearch.com/polypropylenemarket.html Distribution Automation Market: http://www.transparencymarketresearch.com/distribution-automation-market.html Continuous Glucose Monitoring Market: http://www.transparencymarketresearch.com/continuous-glucose-monitoring.html 4.1.1.1 Global Preclinical Studies Pharmacovigilance Market Revenue, 2011 2019 (USD Million) 4.1.2 Phase I trial 4.1.2.1 Global Clinical Trial Phase I Pharmacovigilance Market Revenue, 2011 2019 (USD Million) 4.1.3 Phase II trial 4.1.3.1 Global Clinical Trial Phase II Pharmacovigilance Market Revenue, 2011 2019 (USD Million) 4.1.4 Phase III trial 4.1.4.1 Global Clinical Trial Phase III Pharmacovigilance Market Revenue, 2011 2019 (USD Million) 4.1.5 Phase IV trial (Post marketing surveillance) 4.1.5.1 Global Clinical Trial Phase IV Pharmacovigilance Market Revenue, 2011 2019 (USD Million) Chapter 5 Global Pharmacovigilance Market, By Type of Methods 5.1 Overview 5.1.1 Spontaneous Reporting 5.1.1.1 Global Spontaneous Drug Safety Reporting Market Revenue, 2011 2019 (USD Million) 5.1.2 Targeted Reporting
5.1.2.1 Global Targeted Drug Safety Reporting Market Revenue, 2011 2019 (USD Million) 5.1.3 Cohort Event Monitoring 5.1.3.1 Global Cohort Event Monitoring Market Revenue, 2011 2019 (USD Million) 5.1.4 EHR Monitoring 5.1.4.1 Global Electronic Health Records (EHR) Monitoring Market Revenue, 2011 2019 (USD Million) 5.1.5 Intensified ADR Reporting 5.1.5.1 Global Intensified ADR Reporting Market Revenue, 2011 2019 (USD Million) Chapter 6 Global Pharmacovigilance Market, by Type of Service Providers 6.1 Overview 6.1.1 In-House 6.1.1.1 Global In-House Pharmacovigilance Market Revenue, 2011 2019 (USD Million) 6.1.2 Contract Outsourcing 6.1.2.1 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2011 2019 (USD Million) Chapter 7 Global Pharmacovigilance Market, by Geography 7.1 Overview 7.1.1 Comparative Analysis: Global Pharmacovigilance Market, by Geography, 2012 & 2019 (Value %) 7.2 North America 7.2.1 North America Pharmacovigilance Market Revenue, 2011 2019 (USD Million) 7.3 Europe 7.3.1 Europe Pharmacovigilance Market Revenue, 2011 2019 (USD Million) 7.4 Asia Pacific
Browse TOC of Pharmacovigilance Market Report: http://www.transparencymarketresearch.com/pharmacovigilance-market.html 7.4.1 Asia-Pacific Pharmacovigilance Market Revenue, 2011 2019 (USD Million) 7.5 Rest of the World 7.5.1 Rest of the World Pharmacovigilance Market Revenue, 2011 2019 (USD Million) Chapter 8 Global Pharmacovigilance Market Share Analysis 8.1 Market Share Analysis by Key Players of Global Pharmacovigilance Market 8.1.1 Global CRO Market Share Analysis, by Key Players, 2012 (%) Chapter 9 Recommendations 9.1 Success Strategies 9.1.1 Developing Strategic Alliances and Partnerships With CROs and Life Science BPOs Companies 9.1.2 Hub and Spoke model to optimize drug safety 9.1.3 Enhancing operational activities for better outcomes 9.1.4 Expand Market into Emerging Countries Chapter 10 Company Profiles 10.1 Accenture, Plc 10.1.1 Company Overview 10.1.2 Financial Overview 10.1.3 Product Portfolio 10.1.4 Business Strategies 10.1.4.1 Mergers and acquisitions
10.1.5 Recent Developments 10.2 Bristol-Myers Squibb 10.2.1 Company Profile 10.2.2 Financial overview 10.2.3 Product Portfolio 10.2.4 Business Strategies 10.2.4.1 Strategic collaboration 10.2.4.2 Research and Development Initiatives 10.2.4.3 Recent Developments 10.3 Clinquest Group B.V. 10.3.1 Company Overview 10.3.2 Product Portfolio 10.3.3 Business Strategies 10.3.3.1 Strategic partnership 10.3.4 Recent Developments 10.4 Cognizant Technology Solutions 10.4.1 Company Overview 10.4.2 Financial Overview 10.4.3 Product Portfolio 10.4.4 Business Strategies 10.4.4.1 Expansion of geographical footprint 10.4.4.2 Expansion of product portfolio 10.4.4.3 Highly-skilled manpower 10.4.4.4 Strategic acquisitions 10.4.5 Recent Developments
10.5 Covance, Inc. 10.5.1 Company Overview 10.5.2 Financial Overview 10.5.3 Product Portfolio 10.5.4 Business Strategies 10.5.4.1 New product development and innovation 10.5.4.2 Agreements and collaborations 10.5.4.3 Strategic acquisitions 10.5.4.4 Geographical expansion of business 10.5.5 Recent Developments 10.6 GlaxoSmithKline (GSK) 10.6.1 Company Overview 10.6.2 Financial overview 10.6.3 Product Portfolio 10.6.4 Business strategies 10.6.4.1 Research and development initiatives 10.6.4.2 Direct to Consumer Advertising 10.6.4.3 Mergers and acquisitions 10.6.5 Recent developments 10.7 ICON, Plc 10.7.1 Company Overview 10.7.2 Financial Overview 10.7.3 Product Portfolio 10.7.4 Business Strategies 10.7.4.1 Business expansion in APAC region
Browse TOC of Pharmacovigilance Market Report: http://www.transparencymarketresearch.com/pharmacovigilance-market.html 10.7.4.2 Expansion of services offered 10.7.5 Recent Developments 10.8 igate Corporation 10.8.1 Company Overview 10.8.2 Financial Overview 10.8.3 Product Portfolio 10.8.4 Business Strategies 10.8.4.1 Strategic Acquisition 10.8.5 Recent Developments 10.9 imedglobal Corporation 10.9.1 Company Overview 10.9.2 Product Portfolio 10.9.3 Business Strategies 10.9.3.1 Geographical Expansion 10.9.4 Recent Developments 10.10 Infosys 10.10.1 Company Overview 10.10.2 Financial Overview 10.10.3 Product Portfolio 10.10.4 Business Strategies 10.10.4.1 Extensive product portfolio 10.10.4.2 Geographical expansion of business 10.10.5 Recent Developments
10.11 inventiv Health Inc. 10.11.1 Company Overview 10.11.2 Product Portfolio 10.11.3 Business Strategies 10.11.3.1 Strategic Partnership 10.11.3.2 Strategic Acquisition 10.11.4 Recent Developments 10.12 Johnson and Johnson 10.12.1 Company Profile 10.12.2 Financial Overview 10.12.3 Product Portfolio 10.12.4 Business Strategies 10.12.4.1 Extensive Research and Development Investments 10.12.4.2 Strategic Collaborative Arrangements 10.12.4.3 Recent Developments 10.13 Novartis International AG 10.13.1 Company Overview 10.13.2 Financial Overview 10.13.3 Product Portfolio 10.13.4 Business Strategy 10.13.4.1 Mergers and Acquisitions 10.13.5 Recent Developments 10.14 OptumInsight, Inc. 10.14.1 Company Overview 10.14.2 Product Portfolio
10.14.3 Business Strategies 10.14.3.1 Strategic product launch 10.14.3.2 Strategic collaboration 10.14.4 Recent Developments 10.15 Parexel International Corporation 10.15.1 Company Overview 10.15.2 Financial Overview 10.15.3 Product Portfolio 10.15.3.1 Strong presence in Asia and emerging markets 10.15.3.2 Strategic alliances 10.15.3.3 Mergers & Acquisitions 10.15.4 Recent Developments 10.16 Pfizer, Inc. 10.16.1 Company Overview 10.16.2 Financial Overview 10.16.3 Product Portfolio 10.16.4 Business Strategies 10.16.4.1 Acquisitions 10.16.5 Recent Developments 10.17 Pharmaceutical Product Development, Inc. (PPD, Inc.) 10.17.1 Company Overview 10.17.2 Product Portfolio 10.17.3 Business Strategies 10.17.3.1 Expanding geographic presence 10.17.3.2 Incorporation of innovative technologies
10.17.3.3 Strategic acquisitions 10.17.3.4 New product launch and innovation 10.17.4 Recent Developments 10.18 PRA International, Inc. 10.18.1 Company Overview 10.18.2 Product Portfolio 10.18.3 Business Strategies 10.18.3.1 Mergers and acquisitions 10.18.4 Recent Developments 10.19 Quantum Solutions India 10.19.1 Company Overview 10.19.2 Product Portfolio 10.19.3 Business Strategies 10.19.3.1 Strategic Collaborations 10.20 Quintiles Transnational Corporation 10.20.1 Company Overview 10.20.2 Financial Overview 10.20.3 Product Portfolio 10.20.4 Business Strategies 10.20.4.1 Expansion of services 10.20.4.2 Acquisitions and partnerships 10.20.4.3 Innovation in services offered 10.20.5 Recent Developments 10.21 F. Hoffmann-La Roche Ltd. 10.21.1 Company Overview
10.21.2 Financial Overview 10.21.3 Product Portfolio 10.21.4 Business Strategies 10.21.4.1 Licensing Agreement 10.21.4.2 Product portfolio expansion 10.22 Sanofi Aventis 10.22.1 Company Overview 10.22.2 Financial Overview 10.22.3 Product Portfolio 10.22.4 Business Strategy 10.22.4.1 Renewal of cooperation protocol 10.22.4.2 Recent developments 10.23 Synowledge LLC 10.23.1 Company Overview 10.23.2 Product Portfolio 10.23.3 Business Strategies 10.23.3.1 Geographical Expansion 10.23.3.2 Strategic Partnership 10.23.4 Recent Developments 10.24 United BioSource Corporation 10.24.1 Company Overview 10.24.2 Product Profiling 10.24.3 Business Strategies 10.24.3.1 Strategic acquisitions 10.25 Wipro Limited
Browse TOC of Pharmacovigilance Market Report: http://www.transparencymarketresearch.com/pharmacovigilance-market.html 10.25.1 Company Overview 10.25.2 Financial Overview 10.25.3 Product Portfolio 10.25.4 Business Strategies 10.25.4.1 Geographical expansion About Us: Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Contact: Transparency Market Research 90 State Street, Suite 700, Albany NY 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ Related Blogs: https://vaibhavmondhe.wordpress.com https://usamarketresearch.wordpress.com/ https://pharmaceuticalmarkets.wordpress.com/ https://medicaldevicesreports.wordpress.com/ https://chemicalandmaterials.wordpress.com/